
NYSEHealthcareDrug Manufacturers - General
最新資料
US$174.35
−US$1.06 · -0.60%
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
前收盤價
US$174.35
−US$1.06 · -0.60%
盤中時間採用ET。市場資料可能有所延遲。
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
日內區間
目前US$174.35
52週區間
目前US$174.35
盤中時間採用ET。市場資料可能有所延遲。
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
日內區間
目前US$174.35
52週區間
目前US$174.35
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 587.39億 USD | 540.73億 USD | 458.11億 USD | 443.51億 USD | 374.17億 USD |
| 銷貨成本 | 106.33億 USD | 102.07億 USD | 82.68億 USD | 123.91億 USD | 124.37億 USD |
| 毛利 | 481.06億 USD | 438.66億 USD | 375.43億 USD | 319.6億 USD | 249.8億 USD |
| 研究與開發 | 142.32億 USD | 135.83億 USD | 109.35億 USD | 97.62億 USD | 97.36億 USD |
| 銷售、一般及管理費用 | 205.12億 USD | 202.24億 USD | 182.22億 USD | 179.84億 USD | 155.9億 USD |
| 營業費用 | 343.63億 USD | 338.63億 USD | 293.5億 USD | 282.03億 USD | 239.24億 USD |
| 利息收入 | 3.6億 USD | 3.45億 USD | 3.01億 USD | 8100萬 USD | 4300萬 USD |
| 利息支出 | 16.94億 USD | 16.82億 USD | 15.89億 USD | 13.3億 USD | 12.76億 USD |
| 折舊和攤銷 | 57.33億 USD | 50.65億 USD | 49.34億 USD | 52.54億 USD | 41.02億 USD |
| 營業利益 | 137.43億 USD | 100.03億 USD | 81.93億 USD | 37.57億 USD | 10.56億 USD |
| 淨利 | 102.55億 USD | 70.35億 USD | 59.55億 USD | 32.88億 USD | 1.12億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Dimensional International High Profitability ETFDIHP6257.68萬0.99%62.14億 USD0.27%US$31.59-2.35%
WisdomTree International Hedged Quality Dividend Growth FundIHDG5877.22萬2.88%21.11億 USD0.58%US$49.47-2.66%
Dimensional - International Core Equity 2 ETFDFIC5106.04萬0.35%144.85億 USD0.22%US$34.86-2.41%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ3939.36萬3.08%12億 USD0.48%US$32.48-3.39%
VanEck Pharmaceutical ETFPPH3779.52萬3.70%10.21億 USD0.36%US$114.85-0.09%
First Trust Value Line Dividend Index FundFVD3353.87萬0.42%79.19億 USD0.62%US$49.92-0.46%
Dimensional World ex U.S. Core Equity 2 ETFDFAX2450.27萬0.21%112.84億 USD0.28%US$32.48-3.53%
WisdomTree International Quality Dividend Growth FundIQDG1970.79萬2.92%6.87億 USD0.42%US$39.62-2.46%
Dimensional International High Profitability ETFDIHP
WisdomTree International Hedged Quality Dividend Growth FundIHDG
Dimensional - International Core Equity 2 ETFDFIC
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ
VanEck Pharmaceutical ETFPPH
First Trust Value Line Dividend Index FundFVD
Dimensional World ex U.S. Core Equity 2 ETFDFAX
WisdomTree International Quality Dividend Growth FundIQDGAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。